Trevi Therapeutics Inc (TRVI) 2021 Q3 法說會逐字稿

Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2021 Earnings Conference Call. (Operator Instructions)

Please note, this event may be recorded.

The various remarks that management makes during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company's most recent quarterly report on Form 10-Q, which the company filed with the SEC this afternoon.

In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change.

Participating on today's call from Trevi Therapeutics are Jennifer Good, President and CEO; Bill Forbes, Chief Development Officer; and Lisa Delfini, Chief Financial Officer.

I would now like to turn the conference over to Jennifer. Please go ahead.

Good afternoon, and welcome to our third quarter 2021 earnings call and business update. As mentioned, joining me today on this call are Lisa Delfini, our CFO; Bill Forbes, our Chief Development Officer. Lisa and I have some prepared remarks, then the 3 of us will be available for questions at the end.

As we head into the end of the year, we are excited to share the progress we've made on enrollment for both of our trials. I will give you a bit more color on the progress and how we're preparing for the next stages in development.

Our most advanced program in clinical development is in severe chronic pruritus and prurigo nodularis or PN, which is a serious and debilitating disease characterized by papules and nodules on the skin as well as incessant and severe itching. There are no approved therapies for this indication. Prurigo nodularis is a chronic neuroinflammatory disease, and because of the repeated scratching, patients are stuck in a hard to break itch-scratch cycle.

Due to the scratching, the papules and nodules continue to develop and worsen across the patient's body. We estimate the global prevalence of PN is approximately 730,000 patients with 300,000 patients in the U.S. and 430,000 in the rest of the world.

We believe in the potential and utility of our mechanism of action in this indication, along with the benefit of being an oral candidate in late-phase development. This positions us with an important competitive advantage and a potentially valuable option for patients in a space where the majority of compounds in development are biologics.

We are currently conducting a Phase IIb/III trial in this condition, which we call our PRISM trial. The PRISM trial is recruiting in both the U.S. and Europe, and to date, we have more than 60 sites activated.

The primary endpoint in the study is a responder analysis defined as a 4-point reduction from baseline, as measured by the Worst Itch Numerical Rating Scale. The blinded study includes 14 weeks of dosing.

We currently have randomized approximately 90% of the planned 360 subjects and are excited to be getting to the end of enrollment and closer to top line data. The percentage of subjects continuing into the open-label extension remains high at also approximately 90%. This will provide not only long-term safety data but also important efficacy data around skin healing and quality of life for these subjects.

We believe that by treating the symptomatic endpoint of reducing itch, that an effective therapy has the potential to disrupt the itch-scratch cycle, leading to skin healing and resulting in disease modifications over time. We are taking photographs at certain sites in the study and continue to hear good success anecdotes from patients on long-term therapy, who we know are on drug in our open-label extension. There is also an investigator-initiated study in Germany, which is tracking the return of itch for subjects who have completed 1 year of therapy on Haduvio.

The investigators are studying subjects for a year once they complete therapy for the return of itch, the use of concomitant meds and the overall health of the skin. This will provide valuable data for clinicians about the disruption of the itch-scratch cycle, regional healing and how long those benefits last.

Turning now to our second clinical program, which is in chronic cough in idiopathic pulmonary fibrosis or IPF. IPF is a progressive and severe condition in which there is scarring of the lung tissues. One of the leading debilitating symptoms of this disease is chronic coughing, which affects up to 70% to 85% of these patients and for which there are no approved therapies. In the U.S., we estimate that there are approximately 130,000 patients with IPF and an equal amount in Europe.

Due to the high 5-year mortality associated with IPF, prescribers and patients are not only looking to slow the progression of the disease, but also improve the patient's quality of life. Also, chronic cough and IPF is an indication in a much larger opportunity for chronic cough, both in other interstitial lung diseases as well as the growing opportunity in refractory chronic costs. Both are markets we will consider for further clinical development with positive data in IPF cough.

We are conducting a Phase II double-blind crossover study with a 14-day washout period between each 3-week treatment arm. The primary endpoint assessment is the mean percent change in daytime cough frequency from baseline. The daytime cough frequency is measured by a digital cough monitor between the treatment and placebo arms. This trial is currently being conducted in the U.K. and because of the lung impairment associated with this disease, this trial has been more significantly impacted by COVID-19 restrictions than our PN study. However, the restrictions were eased over the summer and continue that way.

This study is designed to enroll approximately 60 subjects with a goal of getting 44 completers. We have reopened 10 of our targeted 15 sites in the U.K., and we are pleased to see those sites screening and enrolling subjects. We have seen steady activity, which has continued into November. We will continue to work closely with our remaining qualified sites in the U.K. to get them up and enrolling as well.

Top line data for this study is expected in the first half of next year. We are coming upon a very important period of clinical data for the company. Over the next few months, we believe we will complete enrollment in both the PN and IPF cough trials and report data on both. These indications are large market opportunities and the potential for indication expansion in both pruritus and chronic cough is significant.

In addition to the focus on completing our trials, the team has also been active preparing for the next stage of development for both of these indications, as well as evaluating other potential indications for future development.

We are also actively publishing our data and participating in conferences. In the past few months, we took part in pulmonary fibrosis awareness month during September, alongside action for pulmonary fibrosis. We also attended Fall Clinical in Las Vegas, the 11th World Congress on Itch, which took place virtually and Bill spoke at a panel discussion, and we were active in the BIO-Europe conference. So it has been a busy time at Trevi.

That's all I have on the business update for the quarter. I will now ask Lisa to review our financial results, and then we will open it up for questions. Lisa?

Thank you, Jennifer, and good afternoon, everyone. As a reminder, the full financial results for the 3 and 9 months ended September 30, 2021, can be found in our press release issued ahead of this call and our 10-Q, which was filed with the SEC today after the market closed.

For the third quarter of 2021, we reported a net loss of $7.3 million compared to a net loss of $7.4 million for the same quarter of 2020. R&D expenses were $4.7 million during the third quarter of 2021 compared to $4.8 million in the same period of 2020. This was primarily due to decreased purchases of clinical trial supplies as we near the end of our trials, partially offset by an increase in personnel-related expenses as a result of an increase in our R&D employee headcount.

G&A expenses were $2.2 million during the third quarter of 2021 compared to $2.4 million in the same period of 2020. This was primarily due to decreased market research costs and lower stock-based compensation expense, partially offset by higher legal and other professional fees.

Other expenses also increased by approximately $161,000 representing a full quarter of interest expense on our term loan with SBB, which was executed in August of 2020.

As of September 30, 2021, our cash and cash equivalents totaled $29.3 million compared to $45 million as of December 31, 2020.

Subsequent to the end of the quarter, we raised $14.8 million through the sale of common stock and warrants to both a new investor and NEA, an existing investor, who also chose to participate. The proceeds will be used to fund the development of Haduvio and company operations.

This concludes our prepared remarks. I will now turn the call back over to the operator for Q&A.

(Operator Instructions) Today's first question comes from Annabel Samimy with Stifel.

This is Nick Rubino on for Annabel. We're just trying to get a sense of expectations for the upcoming PRISM readout. So you've made some several adjustments to hopefully improve the PRISM design from Phase II. Does the benchmark the Phase II results where you saw a 15% delta in that MITT and 30% delta in the completer groups? Or do you have improved expectations for the percent of responders for the 4-point reduction. And then just kind of separately, where does LID sit currently?

Bill, I'll let you take on the PRISM answer, and then I'll comment on LID.

Okay. Nick, this is Bill. Thanks for your questions. So we -- obviously, we did an interim analysis, but that was done by an independent statistician. So if you're talking about the sample size reestimation on PRISM, we don't know what those results were. Obviously, they fell into a promising conditional power zone that was spelled out in the protocol.

And so from that perspective, we feel confident that as the study continued to perform the way that it was that the current PRISM study as it's designed and powered should reflect positive results based on that interim analysis. So I don't know if that answers your question, Nick, as far as kind of the delta between the active and placebo?

Yes. That's definitely helpful. I guess in terms of -- you provided kind of a Phase II look at what we saw in terms of...

You're referring to the previous study?

Yes.

Yes. No. I mean I think -- look, in this particular study that -- the previous study was just a little over 60 patients and 3 treatment groups. Obviously, the current study, 360 patients in 2 treatment groups. Obviously, we feel pretty good that we're powered to where we need to be to show a difference between active and placebo on this, based on those results on the previous study. So obviously, this is about execution at this point in time.

I can tell you that the centers are anxious to finish this study. I mean they've had a very good October. The screenings in November have been very good. So we hope that we can continue to drive this and get to the analysis part of this study. Obviously, it's a 14-week double-blind period. So that's why we say and we're guiding towards reading up results sometime in the first half of next year.

Great. Nick, that was a crystal ball question we all ask Bill every week. But unfortunately, he doesn't know, but I'm glad you asked it. Your question on LID, it's an indication we still continue to be quite interested in. We've got the IP rights around that. What I would say is, as we've communicated, we're going to -- we're focused on these 2 indications.

Depending on the data in both, we've looked at other opportunities to expand within pruritus and cough and also sort of the opportunity in LID. And I think there will be a good sort of strategy decision based on final results from both trials where we head next and sort of what we can absorb and afford. So I would say it's still on the table, but it will be evaluated against other opportunities in the pruritus and cough space as well.

(Operator Instructions) Our next question comes from Rohit Bhasin with Needham & Company.

This is Rohit on for Serge. What are your thoughts on the recent Dupixent Phase III results in PN? And where do you see that products fitting in the treatment paradigm for PN?

Yes, it's a good question. So we looked at the results. I generally try to not comment on others. I think the good news is, it's a tough condition. They have statistical significance, which is obviously good for the patient. I mean everybody knows Dupixent is a good drug. They've done great with it. The results weren't so daunting though that I think that they're beatable, if you will.

So I think that is a good opportunity for us. This is a market that's become pretty biologics entrenched. So my own feeling on it, this is a personal opinion. I was glad the drug worked, but I was glad it was not overwhelming results either because I think that puts us in a really good position as an oral therapy to be in that treatment paradigm. So we obviously have our eye on the ball about how we become step-through therapy to the biologics, but it will depend on our own results and our own label to be able to do that.

Great. And just as a follow-up, was the enrollment in the PRISM trial affected at all by Dupixent trial at all?

Not so much Dupixent because they had a lot of sites in different countries, China, Russia, kind of Iran, Europe. We crisscrossed with them in a couple of sites. So I would not say we were so affected by Dupixent. I think they finished enrollment in their second trial, so they're out of the way. But we did not run into them all that much out in the field.

Ladies and gentlemen, this concludes our question-and-answer session. I'd like to turn the conference back over to Jennifer Good for any closing remarks.

We would like to thank everybody for participating in today's call. I'd also like to thank the Trevi team, our study investigators and all the subjects who continue to participate in our clinical trials. We will be at several conferences over the next 3 months, starting with the Stifel Healthcare Conference next week. We hope to see you there. Thank you.

And thank you. This concludes today's conference call. We thank you all for attending today's presentation. You may disconnect your lines, and have a wonderful day.